During the Education Session “Tobacco Cessation and CT Screening Recommendations for Patients With Lung Cancer,” to be held on June 4, experts will discuss strategies for implementing lung cancer screening programs.
How to best manage issues that are common in older patients with advanced non–small cell lung cancer will be the focus of the Education Session “Lung Cancer in the Older Population: Caring for the Whole Patient."
Results from a phase I study conducted in patients with relapsed or refractory metastatic disease revealed that single-agent treatment with the antibody-drug conjugate delivered a powerful blow to tumors bearing delta-like protein 3.
The NLST launched lung cancer screening, and since then, guidelines and recommendations have continued to evolve. Experts discussed rationale for lung screening, practical issues with screening implementation, and the enormous opportunity of addressing tobacco use during an Education Session.
The combination of the checkpoint inhibitor nivolumab with or without the anti–CTLA-4 ipilimumab resulted in durable objective responses for relapsed small cell lung cancer, regardless of platinum sensitivity or tumor PD-L1 expression.
Immune checkpoint inhibitors show promise in combating lung cancer and other malignancies by altering the tumor microenvironment and blocking the immune system evasion that allows cancers to grow and proliferate.
Dr. Paul A. Bunn, Jr., is honored with the 2016 David A. Karnofsky Memorial Award and Lecture for establishing new lung cancer diagnostics and treatment strategies, which have led to dramatically improved outcomes in patients with lung cancer.
Three speakers will highlight importance of effective smoking cessation and lung cancer screening programs, as well as practical strategies for implementing these programs during a June 4 Education Session.
The rise of e-cigarette usage has provoked vigorous debate within the public health community and among health care providers, despite the common goal of getting patients to be completely smoke and vape free.
New recommendations will include a large guideline update on the use of systemic treatment for patients with stage IV non–small cell lung cancer and cover the rapidly advancing area of molecular testing for patients with either early-stage or advanced lung cancer.
Results from the phase III IFCT-GFPC-0701 MAPS trial found that the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma prolonged overall survival by 2.75 months.
The high-affinity, humanized monoclonal PD-1 antibody pembrolizumab showed promising antitumor activity in heavily pretreated, PD-L1-positive patients with extensive-stage small cell lung cancer in the KEYNOTE-028 trial.
In patients with advanced nsNSCLC, a chemotherapy regimen including pemetrexed had a better safety profile than one including etoposide, but demonstrated no improvement in survival outcomes. Routine use of the regimen may be questionable, given its considerably higher cost.